Genomtec S.A. Mobile molecular diagnostics
An innovative Polish medical-technology company developing and commercialising Genomtec®ID a mobile molecular diagnostics platform for infectious-disease detection using proprietary SNAAT® isothermal chemistry and microfluidic chip technology designed to deliver PCR-grade results at the point of care.
Genomtec S.A. Investor Relations Video Hub
All CEO & CFO video presentations from Genomtec S.A. filter by format below to find what you need.
Genomtec S.A. Elevator Pitch | Revolutionizing Diagnostics with an Innovative Mobile Molecular Platform
Explore Genomtec's game-changing mobile molecular diagnostics platform, Genomtec®ID, and its potential to transform point-of-care testing for infectious diseases, including COVID-19.
Watch presentation
Mobile molecular diagnostics
Genomtec is an innovative medical-technology company dedicated to the development and commercialisation of Genomtec®ID a mobile molecular diagnostics platform for the detection of various infectious diseases. The platform addresses a structural gap between centralised laboratory PCR testing and existing rapid antigen tests by bringing molecular-grade accuracy into decentralised, point-of-care settings.
Genomtec®ID: A Mobile IVD Platform
The Company's flagship project is the Genomtec®ID mobile in-vitro diagnostics platform. The analyser is uniquely placed among Point-of-Care (POC) products worldwide, allowing for quick and precise clinical molecular analysis outside the standard laboratory setting, without the need to involve qualified laboratory personnel. The system uses microfluidic technology and the proprietary, patent-protected SNAAT® isothermal chemistry enabling diagnostic workflows in as little as 15 minutes, with parameters comparable to or exceeding those of established PCR tests.
Development and Manufacturing Process
The development and manufacturing process is executed in close cooperation with international CMO (Contract Manufacturing Organisation) partners. This model lets Genomtec scale its supply base without the upfront capital intensity of in-house manufacturing, while retaining ownership of the intellectual property that underpins the platform.
Commercialisation & Pipeline
Beyond Genomtec®ID, the Group has manufactured Genomtec® SARS-CoV-2 EvaGreen® laboratory tests based on RT-LAMP technology in Poland with CE-IVD market authorisation in the European Union and registration activities in other jurisdictions. The combined commercial and pipeline portfolio targets infectious-disease detection across hospital, clinic, and decentralised testing environments.
Want your company
on seat11a?
Join Genomtec and 100+ listed companies reaching institutional investors through CEO and CFO video presentations.